Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Angiogenesis library

Preferred format:
Desirable size of the custom library selection:
  • Mg
  • uMol

An extensive collection of compounds inhibiting angiogenesis contains 17,000 entries.

Angiogenesis is a critical physiological process that describes the development of new blood vessels from those already existing, a progression from the initial phase of vasculogenesis. This process involves the intricate mechanisms of sprouting and splitting to expand the vascular network. Vasculogenesis, occurring during embryonic development, entails the formation of endothelial cells from mesodermal cell precursors, contributing to the early vascular structure. Once vasculogenesis establishes the primary vessels, angiogenesis becomes the principal driver of vascular growth, both in normal development and in pathological states.

Essential for normal growth, development, and healing processes, such as in wound repair and granulation tissue formation, angiogenesis plays a dual role. Notably, it is also implicated in the progression of tumors from benign to malignant stages. This critical role of angiogenesis in tumor growth has led to the development and use of angiogenesis inhibitors, a significant approach in cancer therapy targeting the vascular support system of tumors to inhibit their growth and spread.

This specialized library of chemical compounds, focused on targeting proteins involved in angiogenesis, stands as a pivotal resource in the realm of drug discovery. Its primary benefit lies in its targeted approach, specifically honing in on the angiogenesis process—a critical pathway in various physiological and pathological conditions, including cancer, cardiovascular diseases, and wound healing. By concentrating on this specific mechanism, the library offers significant potential for the development of novel therapeutics that can effectively inhibit angiogenesis in tumor cells. Researchers can leverage this library to identify compounds that either promote or inhibit angiogenesis, making it invaluable for developing treatments for a wide array of diseases where angiogenesis plays a key role.

The chemical diversity within this library is another of its significant attributes. It encompasses a vast array of compounds, each possessing unique structures and properties, thereby covering a broad spectrum of chemical space. This diversity is crucial for the identification of potent and selective inhibitors or promoters of angiogenesis. The compounds vary in their size, shape, and functional groups, allowing for the exploration of a multitude of interactions with angiogenic proteins. Such variety not only increases the chances of discovering effective drug candidates but also aids in understanding the complex biochemistry of angiogenesis, paving the way for more innovative approaches in drug design.

From the perspective of anticancer drug discovery, this library offers promising avenues. Since angiogenesis is a fundamental process in tumor growth and metastasis, targeting angiogenic pathways has become a strategic approach in cancer therapy. The compounds in this library, with their focus on angiogenic proteins, present opportunities to disrupt the vascular support of tumors, thereby inhibiting their growth and spread. The library's diversity and specificity make it an essential tool for developing next-generation anticancer drugs, potentially leading to more effective and targeted therapies with fewer side effects. As cancer research continues to evolve, such libraries will be instrumental in the quest to develop more sophisticated and personalized treatment options.

The library's targeted focus on key angiogenesis-related proteins further enhances its value in drug discovery. It encompasses a range of critical targets, such as

●      VEGFR (Vascular Endothelial Growth Factor Receptor),

●      FGFR (Fibroblast Growth Factor Receptor),

●      PDGFR (Platelet-Derived Growth Factor Receptor),

●      EGFR (Epidermal Growth Factor Receptor),

●      FLT3 (Fms-like Tyrosine Kinase 3).

●      FAK (Focal Adhesion Kinase),

●      JAK-1,2 (Janus Kinases 1 and 2),

●      TIE-1,2 (Tyrosine Kinase with Immunoglobulin-like and EGF-like Domains 1 and 2).

These targets play pivotal roles in the modulation of angiogenesis, making them critical points of intervention for therapeutic development. By focusing on these specific proteins, the library offers a strategic approach to disrupting key signaling pathways involved in angiogenesis, thereby providing a robust platform for the identification of potential drug candidates with high efficacy and specificity in treating angiogenesis-related disorders, particularly in the context of cancer.

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote